Amarillo Biosciences Inc. (AMAR) Releases Earnings Results
Amarillo Biosciences Inc. (OTCMKTS:AMAR) posted its quarterly earnings data on Monday. The company reported ($0.01) EPS for the quarter, Bloomberg Earnings reports.
Shares of Amarillo Biosciences (OTCMKTS AMAR) opened at $0.23 on Wednesday. Amarillo Biosciences has a 12 month low of $0.15 and a 12 month high of $0.30.
WARNING: This piece was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://www.watchlistnews.com/amarillo-biosciences-inc-amar-releases-earnings-results/1719590.html.
In other news, CEO Stephen T. Chen acquired 203,000 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were bought at an average price of $0.19 per share, with a total value of $38,570.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders bought a total of 230,739 shares of company stock worth $46,030 in the last three months.
About Amarillo Biosciences
Amarillo Biosciences, Inc is engaged in the business of biopharmaceutical research and development. The Company develops biologics for the treatment of human and animal diseases. The Company’s focus is research aimed at the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia and other indications using natural human interferon alpha that is administered in a low dose oral form.
Receive News & Ratings for Amarillo Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarillo Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.